Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16626917 | 0.94 | HSP90AB1 (0.51) | HSP90AB1ALDH1A1KDM4ECYP19A1SMN1; SMN2 | |
| SCHEMBL16626921 | 0.80 | HSP90AB1 (0.54) | HSP90AB1ALDH1A1CYP19A1 | |
| SCHEMBL16620124 | 0.80 | HSP90AB1 (0.61) | HSP90AB1CYP19A1 | |
| SCHEMBL16626927 | 0.78 | RXRA (0.47) | ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL18028297 | 0.77 | HSP90AB1 (0.70) | HSP90AB1CYP19A1 | |
| SCHEMBL16626918 | 0.77 | ALDH1A1 (0.49) | HSP90AB1ALDH1A1SMN1; SMN2 | |
| SCHEMBL18028307 | 0.75 | HSP90AA1 (0.45) | HSP90AB1ALDH1A1KDM4ESMN1; SMN2KDM1A | |
| SCHEMBL6712868 | 0.73 | KDM4E (0.61) | ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL16619998 | 0.72 | ALDH1A1 (0.48) | ALDH1A1KDM1A | |
| SCHEMBL16626941 | 0.69 | P2RX7 (0.56) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160244431-A1 | Inhibitors of Metallo-Beta-Lactamase (MBL) Comprising a Zinc Chelating Moiety | UNIVERSITETET I OSLO (NO) | 2016-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244431-A1 | Inhibitors of Metallo-Beta-Lactamase (MBL) Comprising a Zinc Chelating Moiety | SLC30A6, DDO, SLC30A7 | HSP90AB1 1862/4885ALDH1A1 1313/4885KDM4E 2892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.